

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### **STA Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equalities issues raised at scoping.

The company noted that increased access to targeted therapies, including zanidatamab if recommended, has the potential to reduce health inequalities since there is a higher incidence of biliary tract cancer and poorer treatment outcomes in socio-economically deprived populations in England. The company's submission provided some evidence that there are socioeconomic differences in mortality rates for biliary tract cancer.

The committee considered this evidence in its deliberations, alongside the nature of the condition and uncaptured benefits. It was unclear to what extent, if any, that zanidatamab would reduce health inequality. The committee concluded that it had not seen robust evidence to show that the technology substantially affects health inequalities which it could consider in its decision making.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No further equality issues raised.

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

N/A

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No.

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, section 3.16 of the draft guidance.

**Approved by Associate Director (name):** .....Lorna Dunning.....

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments

**Date:** 22/12/2025

Technology appraisals: Guidance development  
Equality impact assessment for the single technology appraisal of Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments

3 of 3

Issue date: January 2026